Biotest AG announce that its product Cytotect® CP Biotest has gained marketing authorizations in five additional markets, namely Slovakia, Czech Republic, Lithuania, Romania and Ireland. With these new authorizations, Biotest's hyperimmunoglobulin has now marketing authorizations in 28 countries, most of them in Europe. This further enlarges the footprint of Biotest's CMV-hyperimmunoglobulin in Europe, and reinforces Biotest's commitment to providing life-saving treatments to patients in need.

Biotest's hyperimmunoglobulin is a human cytomegalovirus immunoglobulin, which is used for the prophylaxis of clinical manifestations of CMV infections in patients who receive immunosuppressive therapy, particularly after they have undergone solid organ or stem cell transplantation. CMV infections can cause serious complications in those vulnerable patients who have received transplants, and Cytotect® CP Biotest is an important tool in reducing the risk of such infections. With these new marketing authorizations, even more vulnerable transplant patients can benefit from the protection provided by Biotest's CMV-hyperimmunoglobulin.

The marketing authorizations for Biotest's CMV-hyperimmunoglobulin were granted following a thorough review of clinical data including the well-characterised safety profile by the corresponding national authorities. Worldwide, Biotest is one of only two providers of this class of product, with Cytotect® CP Biotest being the only CMV-hyperimmunoglobulin available in Europe. Biotest AG is committed to ensuring the safety and efficacy of all its products, and the approval of Biotest's CMV-hyperimmunoglobulin in these markets is a testament to the company's rigorous approach to drug development.